INNATE PHARMA SP.ADR/1 (IDDA) - Total Assets
Based on the latest financial reports, INNATE PHARMA SP.ADR/1 (IDDA) holds total assets worth €62.72 Million EUR (≈ $73.33 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore IDDA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
INNATE PHARMA SP.ADR/1 - Total Assets Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's total assets have evolved over time, based on quarterly financial data. See INNATE PHARMA SP.ADR/1 (IDDA) shareholders funds for net asset value and shareholders' equity analysis.
INNATE PHARMA SP.ADR/1 - Asset Composition Analysis
Current Asset Composition (December 2025)
INNATE PHARMA SP.ADR/1's total assets of €62.72 Million consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.8% |
| Accounts Receivable | €391.00K | 0.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INNATE PHARMA SP.ADR/1's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INNATE PHARMA SP.ADR/1 stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INNATE PHARMA SP.ADR/1's current assets represent 74.5% of total assets in 2025, an increase from 51.7% in 2021.
- Cash Position: Cash and equivalents constituted 44.8% of total assets in 2025, up from 38.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 16.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
INNATE PHARMA SP.ADR/1 Competitors by Total Assets
Key competitors of INNATE PHARMA SP.ADR/1 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
INNATE PHARMA SP.ADR/1 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 2.60 | 2.92 |
| Quick Ratio | 1.27 | 2.60 | 2.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €10.06 Million | €52.76 Million | €73.37 Million |
INNATE PHARMA SP.ADR/1 - Advanced Valuation Insights
This section examines the relationship between INNATE PHARMA SP.ADR/1's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.05 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | -43.5% |
| Total Assets | €62.72 Million |
| Market Capitalization | $116.15 Million USD |
Valuation Analysis
Above Book Valuation: The market values INNATE PHARMA SP.ADR/1's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: INNATE PHARMA SP.ADR/1's assets decreased by 43.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below shows the annual total assets of INNATE PHARMA SP.ADR/1 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €62.72 Million ≈ $73.33 Million |
-43.53% |
| 2024-12-31 | €111.06 Million ≈ $129.84 Million |
-36.61% |
| 2023-12-31 | €175.19 Million ≈ $204.81 Million |
-12.10% |
| 2022-12-31 | €199.29 Million ≈ $233.00 Million |
-25.50% |
| 2021-12-31 | €267.50 Million ≈ $312.73 Million |
-- |
About INNATE PHARMA SP.ADR/1
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Mo… Read more